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Abstract
Introduction: Nocturnal hypoxia is an important factor in increasing the risk of mortality in 
patients with chronic heart failure and is associated with atrial and ventricular arrhythmias. 
In addition, QT dispersion (QTd) is used as a prognostic sign in determining future 
malignant arrhythmias and sudden cardiac death. In the current study, we investigated 
the effect of nocturnal oxygen therapy (NOT) on electrocardiographic changes among 
patients with chronic heart failure.
Methods: In this study, a consecutive of 154 patients (87 males and 67 females) known 
with chronic heart failure (EF ≤ 40%) were enrolled. The patients were administered NOT 
(oxygen flow of 2 L/min for 8 hours during sleeping). Electrocardiography was taken 
before and after the NOT, and RR interval, PR interval and QTd were measured each time.
Results: The mean age of the participants was 61.3 ± 11.4 years. Our results revealed 
significant reduction in QTd (55.8 ± 7.5 vs. 61.4 ± 9.1 msec, P = 0.001) and heart rate 
(79.6 ± 4.7 vs. 76.8 ± 4.3, P = 0.001) in a patient’s electrocardiogram after NOT.
Conclusions: In this study, NOT decreased heart rate and QTd in patients with chronic 
heart failure, but not PR interval, which could consequently decrease the risk of malignant 
arrhythmias and sudden cardiac death.
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Chronic heart failure (CHF) is one of the most import-
ant problems in cardiovascular diseases. About 2% of the 
adult population suffers from heart failure, with 50% mor-
tality during five years and with a high economic cost due to 
frequent and prolonged hospitalizations for hemodynamic 
decompensation [1, 2]. The prognosis of patients with CHF 
remains poor, despite the introduction of many effective drugs 
in clinical settings. One of the cardiac pathophysiologic abnor-
malities that worsens heart failure is activation of the sympa-
thetic nervous system [3]. Among patients with CHF, sudden 
cardiac death occurs in 50% as of fatal ventricular arrhythmias, 
particularly ventricular tachycardia and fibrillation [4].
QT dispersion (QTd) is defined as the difference between 
the longest and the shortest QT intervals as measured in the 
12-lead electrocardiogram (ECG). It can be assessed comput-
erized and manually. QTd as a marker of ventricular repolar-
ization inhomogeneity may be a potential prognostic sign in 
the detection of future ventricular tachyarrhythmic events and 
death [5]. Many factors may affect QTd. Nocturnal hypoxia is 
associated with atrial and ventricular arrhythmias in patients 
with chronic heart failure and is an important factor increas-
ing the risk of mortality. Furthermore, smoking may acutlely 
increase QTd, which may be due to hypoxia or other harmful 
changes in the electrical function of myocardial cells [6, 7].
Despite significant advances in the treatment of chronic heart 
failure, mortality and morbidity remain high [8]. Therefore, 
in this study we aimed to investigate the effect of nocturnal 
oxygen therapy (NOT) on QTd in patients with CHF.
METHODS
The protocol for this study was approved by the Medical Ethics 
Committee of Shahid Beheshti University of Medical Sciences. 
Between June 2015 and October 2016, a consecutive of 154 pa-
tients with CHF with etiologies including coronary artery dis-
ease, idiopathic dilated cardiomyopathy, valvular heart disease, 
or hypertensive heart disease were enrolled in this prospective 
study. Patients were excluded if they had atrial fibrillation, 
pacemaker dependency, electrolyte imbalance, class I or class 
III antiarrhythmic drug treatment, acute congestive HF, or re-
nal failure requiring hemodialysis. Patients were administered 
NOT, nasal oxygen thrapy with the oxygen flow of 2 L/min for 
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8 hours during sleeping. ECG was taken before and after NOT.
Evaluation of Electrocardiogram
Standard 12-lead ECGs were analyzed at a paper speed of 50 
mm/s. The R-R (interval between two QRS), PR and QT 
intervals were measured in sinus rhythm in all 12 leads, re-
corded simultaneously by two observers. The QT intervals 
were measured from the onset of the QRS to the end of the T 
wave, defined as a return to the baseline. QTd was defined as 
maximum minus minimum QT interval.
Statistical Analysis
All the data were presented as the mean ± SD. Statistical anal-
yses were performed by SPSS statistical software (version 
16.0 for Windows; SPSS Inc., Chicago, IL, USA). Statistical 
analysis was performed using paired t-test for data before and 
after the oxygen therapy. P values less than 0.05 were consid-
ered statistically significant.
RESULTS
A consecutive of 154 patients (87 males and 67 females) 
known with chronic heart failure was enrolled in this study, 
of which 87 (56.4%) had ischemic, 43 (28%) hypertensive, 
15 (9.8%) valvular and 9 (5.8%) non-ischemic dilated car-
diomyopathy as the underlying cause of CHF. The mean ± 
SD age of the participants was 61.3 ± 11.4 years. The demo-
graphic characteristics of patients are represented in Table 1.
The mean ± SD ages of males and females were 61.45± 10.49 
and 60.71± 11.31 years, respectively; there was no significant 
deference between gender (P = 0.3).
Our results revealed that after nocturnal oxygen therapy, 
QTd (55.8 ± 7.5 vs. 61.4 ± 9.1 msec, P = 0.001) and heart rate 
(79.6 ± 4.7 vs. 76.8 ± 4.3, P = 0.001) significantly reduced.
Despite reduction in QTd and heart rate, here in we did not 
reveal any significant changes in PR interval before and after 
the NOT (17.6 ± 2.4 vs. 18.4 ± 2.1 respectively, P = 0.2).
Table 1: Baseline Characteristics
Values, (n=154)
Age, years 61.4 ± 11.2
EF, % 48.3 ± 8.5
Male 87 (56.49)
Diabetes, % 76 (22.1)
Hypertension, % 43 (28)
Ischemic heart disease, % 87 (56.4)
Dilated Cardiomyopathy, % 9 (5.8)
Valvular heart disease 15 (9.8)
Data in table are presented as Mean ± SD or number (%).
DISCUSSION
Our study demonstrated that NOT decreased QTd in pa-
tients with CHF, which could consequently decrease the 
risk of malignant arrhythmias and sudden cardiac death. To 
our knowledge, few reports have investigated the effect of 
NOT on electrocardiogarphic changes among patients with 
CHF. The results of our study were along with previous 
studies, which have demonstrated significantly increased 
QTd values in patients with CHF [9].
It is known that the renin-angiotensin-aldosterone system 
as a mediator of neurohormonal activation and the sympa-
thetic nervous system are the two most important factors in 
the progression of CHF [10]. Activation of these systems 
is suggested as relating to a poor prognosis in patients with 
CHF [11]. Sympathetic activation or vagal withdrawal at 
the level of the sinoatrial node will increase the heart rate 
and shorten the RR interval, whereas an increase in sympa-
thetic outflow to the ventricular myocardium will decrease 
the QT interval. A decrease in sympathetic outflow or an 
increase in vagal outflow to the atrio-ventricular node will 
result in PR interval prolongation [12].
Dispersion of ventricular repolarization may represent as 
the substrate for re-entry tachycardia and can be masured 
by QTd. An increased repolarization heterogeneity has 
been approved in the genesis of re-entry and malignant 
ventricular arrhythmias in many studies [13]. The greater 
the QTd, the greater the variability in the timing of electri-
cal recovery within the heart. Many studies have suggested 
that increased Qd can predict sudden death and ventricular 
arrhythmias in patients with CHF or hypertrophic cardio-
myopathy [4].
It is also a predictor for developing ventricular arrhythmias 
in patients with different cardiovascular pathologies, in-
cluding myocardial infarction, vasospastic angina, systemic 
hypertension, long QT intervals, or idiopathic dilated car-
diomyopathy [4, 13]. In a retrospective case control study, 
Bonnar et al. compared the QTd and corrected QTd values 
in patients and left ventricular systolic dysfunction with 
control subjects. The QTd and corrected QTd values were 
significantly higher in patients with impaired left ventricular 
systolic function than controls [14].
In addition, it is known that in patients with obstractive 
sleep apnea, hypoxia significantly increases the heart rate 
and shortens the QT interval, and these changes are great-
er compared with healthy controls [15]. Our findings were 
similar to a previous study by Piranfar et al., demonstrat-
ing that NOT significantly decreased QTd in patients with 
CHF [16].
In this study, NOT decreased heart rate and QTd in patients 
with CHF, which could consequently decrease the risk of 
malignant arrhythmias and sudden cardiac death.
Table 2: Electrocardiographic Values before and after Nocturnal Oxygen Therapy
Before NOT After NOT P value
Heart Rate 79.6 ± 4.7 76.8 ± 4.3 0.001
PR interval 2.1 ± 18.4 2.4 ± 17.6 0.2
QTd 61.4 ± 9.1 55.8 ± 7.5 0.001
NOT: Nocturnal Oxygen Therapy
Data in table are presented as Mean ± SD.
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